Questionnaires
A questionnaire is an instrument designed to assess (some of) the different aspects that define the QoL of (a specific group of) cancer patients.
If your study is purely for academic use, you will be required to have an Academic User Agreement in order to use our measures. An Academic User Agreement is required for each study and requires no fee.
In order to be able to use the QLQ-C30 and modules you need to obtain the permission via our download process below. By completing the process you are authorised to use the questionnaire in the study you mentioned. For each new study, you will have to enter a new download request.
Conditions of use for Commercial Users
If your study has commercial sponsorship you will be required to have a Commercial User Agreement in order to use our measures. A Commercial User Agreement is required for each study and a fee is requested dependent on the number of patients in the study.
For further details for commercial use, please contact us.
How to know if you are considered as a Commercial User or an Academic User?
If you are unsure of whether you are a commercial user or an academic user , please refer to our Terms and Conditions.
How to obtain the permission to use a module which is not yet fully validated?
Please note that questionnaires which do not have the status “validated” require an additional agreement. You can access the specimen of these modules on their dedicated webpage. You will receive it from one of the QOL administrators via e-mail.
If the questionnaire is validated, your request will be treated by the QOL administrator and you will receive links to the requested measures. If your request contains both validated and non-validated (as from Phase III completed) modules, you will receive them all after signing the agreement for the non-validated ones.
Links for download are valid for 7 days. If you do not download the measures by then, you will have to submit a new request.
List of questionnaires
Code | Name | ||
---|---|---|---|
QLQ-C30 | Quality of Life of Cancer Patients | Core | validated |
PR-SURV19 | Survivorship | Core | IV - in development |
CR-SURV33 | Survivorship | Core | IV - in development |
BR-SURV40 | Survivorship | Core | IV - in development |
PAN | Update of the EORTC QLQ-PAN26 | Module | I / II - in development |
WISP | The WISP project | Module | III - in development |
FinTox | Financial Toxicity | Module | I / II - in development |
ICI | 2054 Immune Checkpoints Inhibitor | Module | I / II - in development |
1749 | Sarcoma | Module | I / II - in development |
RCC | Renal Cancer | Module | I / II - in development |
1750 | Multiple Myeloma (update of MY20) | Module | I / II - in development |
M20MMM | Metastatic malignant melanoma | Module | I / II - in development |
1841 | Male Breast Cancer | Module | I / II - in development |
STO | Gastric Cancer (update of QLQ-STO22) | Module | I / II - in development |
CL | Cutaneous T-cell and B-cell lymphomas | Module | I / II - in development |
CHI | Children 8-14 | Module | I / II - in development |
Bladder | 1942 Bladder cancer (merge of BLM30 and NMIBC24) | Module | I / II - in development |
AYA | Adolescents and Young Adults | Core | III b - in development |
QLQ-ANL27 | Anal Cancer | Module | validated |
QLQ-BM22 | Bone Metastases | Module | validated |
QLQ-BN20 | Brain | Module | validated |
1751 | BN20 update | Module | III - in development |
QLQ-BR23 | Breast | Module | validated |
QLQ-BR45 | Breast Cancer (update of QLQ-BR23) | Module | IV - completed |
QLQ-BRECON23 | Breast Reconstruction | Module | validated |
QLQ-CAX24 | Cancer Cachexia | Module | IV - completed |
QLQ-FA12 | Cancer related Fatigue | Module | validated |
QLQ-CX24 | Cervical | Module | validated |
QLQ-CIPN20 | Chemotherapy-Induced Peripheral Neuropathy | Module | III - completed |
QLQ-BIL21 | Cholangiocarcinoma and Gallbladder Cancer | Module | validated |
QLQ-CLL17 | Chronic Lymphocytic Leukaemia | Module | validated |
QLQ-CML24 | Chronic Myeloid Leukaemia | Module | IV - in development |
QLQ-CR29 | Colorectal | Module | validated |
QLQ-LMC21 | Colorectal Liver Metastases | Module | validated |
QLQ-COMU26 | Communication | Standalone | IV - in development |
QLQ-ELD14 | Elderly Cancer Patients | Module | validated |
MBC | Metastatic Breast Cancer | Module | II - in development |
QLQ-EN24 | Endometrial | Module | validated |
FERT45 + FERT29 | Fertility | Module | I / II - in development |
QLQ-IN-PATSAT32 | Satisfaction with In-Patient Cancer Care | Standalone | validated |
QLQ-STO22 | Gastric | Module | validated |
QLQ-H&N35 | Head & Neck | Module | validated |
QLQ-H&N43 | Head & Neck Cancer (update of QLQ-H&N35) | Module | validated |
QLQ-HCC18 | Hepatocellular Carcinoma | Module | validated |
HCPS73 | Hereditary Cancer Predisposition Syndrome | Module | III - in development |
QLQ-HDC29 | High-Dose Chemotherapy | Module | III - completed |
QLQ-NHL-HG29 | High Grade Non-Hodgkin’s Lymphoma | Module | IV - completed |
QLQ-HL27 | Hodgkin’s Lymphoma | Module | IV - in development |
IADL | IADL in Brain Tumor Patients | Module | IV - in development |
QLQ-INFO25 | Information | Module | validated |
QLQ-NHL-LG20 | Low Grade Non-Hodgkin’s Lymphoma | Module | IV - completed |
QLQ-LC13 | Lung | Module | validated |
QLQ-LC29 | Lung Cancer (update of QLQ-LC13) | Module | validated |
QLQ-MEL38 | Melanoma | Module | III - completed |
QLQ-MY20 | Multiple Myeloma | Module | validated |
QLQ-BLM30 | Muscle Invasive Bladder Cancer | Module | III - completed |
QLQ-GINET21 | Neuroendocrine Carcinoid | Module | validated |
QLQ-NMIBC24 | Non-Muscle-Invasive Bladder Cancer | Module | III - completed |
QLQ-OES18 | Oesophageal | Module | validated |
QLQ-OG25 | Oesophago-Gastric | Module | validated |
QLQ-OPT30 | Ophthalmic Cancer | Module | III - completed |
QLQ-OH15 | Oral Health | Module | validated |
QLQ-OV28 | Ovarian | Module | validated |
QLQ-PAN26 | Pancreatic Cancer | Module | III - completed |
pNET | Pancreatic Neuroendocrine Tumour | Module | III - completed |
QLQ-PR25 | Prostate | Module | validated |
QLQ-C15-PAL | Quality of Life in palliative cancer care patients | Core | validated |
QLQ-PRT20 | Radiation Proctitis | Module | validated |
QLQ-PATSAT-C33 | Satisfaction with Cancer Care – Core questionnaire | Standalone | IV - in development |
QLQ-OUT-PATSAT7 | Satisfaction with Out-Patient Cancer Care | Standalone | IV - in development |
QLQ-SH22 | Sexual Health | Standalone | validated |
QLQ-SWB32 | Spiritual Wellbeing | Standalone | validated |
SURV100 | Survivorship | Core | IV - in development |
SBQ | Symptom-based questionnaire | Standalone | III - completed |
QLQ-TC26 | Testicular Cancer | Module | validated |
QLQ-THY34 | Thyroid Cancer | Module | IV - completed |
QLQ-VU34 | Vulva Cancer | Module | IV - in development |